

Cases from the Community: Clinical Investigators Provide Perspectives on Actual Patients with Pancreatic Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III Unicancer PRODIGE 24/CCTG PA.6 trial evaluating adjuvant modified FOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma demonstrated _____ with modified FOLFIRINOX.
 - a. Significant improvements in disease-free and overall survival
 - b. Significantly higher rates of most Grade 3 or 4 adverse events
 - c. Both a and b
2. According to the 2018 ASCO Clinical Practice Guideline Update, the preferred first-line treatment for metastatic pancreatic cancer in patients who have an ECOG performance status of 2 or a comorbidity profile that precludes more aggressive regimens and who wish to pursue cancer-directed therapy is _____.
 - a. Gemcitabine with *nab* paclitaxel
 - b. FOLFIRINOX
 - c. Gemcitabine monotherapy
3. The ongoing Phase III CanStem111P trial is investigating the addition of _____ to gemcitabine with *nab* paclitaxel as first-line therapy for patients with metastatic pancreatic adenocarcinoma.
 - a. Napabucasin
 - b. PEGPH20
 - c. Pembrolizumab
4. The Phase III PANCREOX study evaluating 5-fluorouracil/leucovorin with or without oxaliplatin as second-line therapy for patients with advanced pancreatic cancer who had previously received gemcitabine-based chemotherapy _____ demonstrate a significant progression-free survival benefit on the oxaliplatin arm.
 - a. Did
 - b. Did not
5. Germline BRCA1/2 mutations occur in _____ of unselected patients with pancreatic cancer.
 - a. Fewer than 10%
 - b. 15% to 25%
 - c. More than 25%